Back to top
more

Bionano Genomics (BNGO)

(Delayed Data from NSDQ)

$1.11 USD

1.11
4,438,896

+0.05 (4.72%)

Updated Mar 31, 2023 04:00 PM ET

After-Market: $1.13 +0.02 (1.80%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.52%
2Buy18.26%
3Hold9.60%
4Sell5.38%
5Strong Sell2.61%
S&P50010.68%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (86 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Balance Sheet

Research for BNGO

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Bionano Genomics, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018
Assets          
Cash & Equivalents 113 251 38 17 17
Receivables 7 5 3 6 5
Notes Receivable 0 0 0 0 0
Inventories 30 12 3 3 1
Other Current Assets 7 4 2 1 1
Total Current Assets 157 272 47 28 23
Net Property & Equipment 18 10 5 2 2
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 118 83 9 0 0
Deposits & Other Assets 3 1 0 0 0
Total Assets 308 377 60 30 25
Liabilities & Shareholders Equity 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018
Notes Payable 0 0 0 0 0
Accounts Payable 13 10 3 3 1
Current Portion Long-Term Debt 0 0 0 20 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 11 10 6 3 3
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 10 1 0 0 0
Total Current Liabilities 36 22 9 26 5
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 16 0 9
Non-Current Capital Leases 4 4 0 0 0
Other Non-Current Liabilities 13 9 0 0 1
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 58 40 25 27 15
Shareholders Equity 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 599 554 179 106 83
Retained Earnings -349 -216 -144 -103 -73
Other Equity -1 -1 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 249 337 35 4 10
Total Liabilities & Shareholder's Equity 308 377 60 30 25
Total Common Equity 249 337 35 4 10
Shares Outstanding 296.90 289.10 189.90 34.20 10.00
Book Value Per Share 0.84 1.17 0.18 0.11 1.01

Fiscal Year End for Bionano Genomics, Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2023 12/31/2022 9/30/2022 6/30/2022 3/31/2022
Assets          
Cash & Equivalents 113 180 187 216 251
Receivables 7 6 5 6 5
Notes Receivable 0 0 0 0 0
Inventories 30 25 21 16 12
Other Current Assets 7 7 4 4 4
Total Current Assets 157 218 216 242 272
Net Property & Equipment 18 16 14 13 10
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 118 79 80 82 83
Deposits & Other Assets 3 1 1 1 1
Total Assets 308 324 322 348 377
Liabilities & Shareholders Equity 3/31/2023 12/31/2022 9/30/2022 6/30/2022 3/31/2022
Notes Payable 0 0 0 0 0
Accounts Payable 13 9 8 7 10
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 11 12 8 9 10
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 10 10 10 1 1
Total Current Liabilities 36 34 28 19 22
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 4 4 4 4 4
Other Non-Current Liabilities 13 0 9 9
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 58 42 37 37 40
Shareholders Equity 3/31/2023 12/31/2022 9/30/2022 6/30/2022 3/31/2022
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 599 594 565 559 554
Retained Earnings -349 -310 -278 -246 -216
Other Equity -1 -2 -2 -2 -1
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 249 282 285 311 337
Total Liabilities & Shareholder's Equity 308 324 322 348 377
Total Common Equity 249 282 285 311 337
Shares Outstanding 296.90 296.90 289.70 289.70 289.10
Book Value Per Share 0.84 0.95 0.98 1.07 1.17